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Background
Vesigenurtacel-L (HS-410), consists of an allogeneic blad-
der cancer cell line, selected for high expression of a series
of tumor antigens that are known to be shared by a high
proportion of bladder tumors. The cell line secretes
gp96-Ig, a modified heat shock protein which delivers cell-
derived antigens to MHC-I via the cross-presentation
pathway, leading to preferential activation of CD8+
cytotoxic T cells. Vesigenurtacel-L was evaluated in
a Phase I trial after treatment with standard of care induc-
tion BCG for safety and immune response.
Methods
Ten patients with non-muscle invasive bladder cancer who
had undergone TURBT, were judged to be at an increased
risk for recurrence, and were either BCG naïve or had
completed previous BCG treatment >12 months prior to
the most recent TURBT were treated with induction BCG
as standard of care and enrolled in the trial. Patients
received up to 15 doses of monotherapy vesigenurtacel-L
at a dose of 106 cells per dose, weekly for 12 weeks
followed by 3 monthly doses. Baseline tumor tissue and
any follow up biopsies were evaluated by immunohisto-
chemistry for tumor infiltrating lymphocytes and expres-
sion of PD-L1.
Results
Vesigenurtacel-L was well tolerated with no treatment-
related Grade 3/4 adverse events. The most common
adverse events were low-grade injection site reactions
consistent with delayed type hypersensitivity. Peripheral
blood mononuclear cells were evaluated by flow cytometry
for detection of circulating leukocyte subsets, regulatory
T cells, myeloid derived suppressor cells, activated T cells
and expression of immune checkpoint molecules
on T cells. Additionally, analyses from pre- and post-
treatment tissue specimens in a subset of patients includ-
ing antigen expression, evaluation of tumor-infiltrating
lymphocytes, PD-L1 expression and T cell receptor
sequencing will be reported, and their extrapolation to an
emerging definition of responder phenotype discussed. For
example, tissue analysis indicates an increase in CD8+
T cells in the bladder after treatment, consistent with the
mechanism of action derived from preclinical models, and
this change appears be correlated to clinical outcome.
Trial registration
Clinical trial information: NCT02010203.
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